Literature DB >> 26550456

miR-128 modulates hepatocellular carcinoma by inhibition of ITGA2 and ITGA5 expression.

Xiaohua Zhao1, Yingfen Wu2, Zhiping Lv3.   

Abstract

Dysregulation of miRNAs is a common feature in human cancers, but this phenomenon has not been studied extensively in hepatocellular carcinoma (HCC). miR-128 has been found to be downregulated in cancer. However its role in HCC remains unclear. miR-128 was underexpressed in HCC tissues and cell lines compared with their normal controls. Additionally, ITGA2 and ITGA5 were predicted as the target genes of miR-128. ITGA2 and ITGA5 were inversely correlated with the expression of miR-128 in HCC cells. Importantly, we demonstrate that the overexpression of miR-128 significantly inhibits HCC cell metastasis and stem-cell like properties via ITGA2 and ITGA5. Our results suggest the existence of a novel miR-128-ITGA pathway and indicate that miR-128 acts as a tumor suppressor during hepatocellular carcinogenesis. These results may provide a promising alternative strategy for the therapeutic treatment of HCC.

Entities:  

Keywords:  ITGA2; ITGA5; hepatocellular carcinoma; miR-128

Year:  2015        PMID: 26550456      PMCID: PMC4626418     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  21 in total

Review 1.  New aspects of integrin signaling in cancer.

Authors:  L V Parise; J Lee; R L Juliano
Journal:  Semin Cancer Biol       Date:  2000-12       Impact factor: 15.707

Review 2.  Role of integrins in cell invasion and migration.

Authors:  John D Hood; David A Cheresh
Journal:  Nat Rev Cancer       Date:  2002-02       Impact factor: 60.716

3.  MicroRNA-128 promotes proliferation in osteosarcoma cells by downregulating PTEN.

Authors:  Lei Shen; Xiao-Dong Chen; Yao-Hui Zhang
Journal:  Tumour Biol       Date:  2013-10-15

4.  MicroRNA-128 promotes cell-cell adhesion in U87 glioma cells via regulation of EphB2.

Authors:  Lina Lin; Xulin Chen; Xuelin Peng; Jianwen Zhou; Hsiang-Fu Kung; Marie C Lin; Songshan Jiang
Journal:  Oncol Rep       Date:  2013-07-05       Impact factor: 3.906

Review 5.  Recent advances in the surgical treatment of hepatocellular carcinoma.

Authors:  Zenichi Morise; Norihiko Kawabe; Hirokazu Tomishige; Hidetoshi Nagata; Jin Kawase; Satoshi Arakawa; Rie Yoshida; Masashi Isetani
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

Review 6.  Epidemiology and management of hepatocellular carcinoma.

Authors:  Ju Dong Yang; Lewis R Roberts
Journal:  Infect Dis Clin North Am       Date:  2010-12       Impact factor: 5.982

Review 7.  Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials.

Authors:  Bruna Scaggiante; Maryam Kazemi; Gabriele Pozzato; Barbara Dapas; Rosella Farra; Mario Grassi; Fabrizio Zanconati; Gabriele Grassi
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

Review 8.  MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches.

Authors:  E Callegari; L Gramantieri; M Domenicali; L D'Abundo; S Sabbioni; M Negrini
Journal:  Cell Death Differ       Date:  2014-09-05       Impact factor: 15.828

9.  MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1.

Authors:  Zhu-mei Shi; Jing Wang; Zhiping Yan; Yong-ping You; Chong-yong Li; Xu Qian; Yu Yin; Peng Zhao; Ying-ying Wang; Xie-feng Wang; Ming-na Li; Ling-Zhi Liu; Ning Liu; Bing-Hua Jiang
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240

10.  Regulation of colony stimulating factor-1 expression and ovarian cancer cell behavior in vitro by miR-128 and miR-152.

Authors:  Ho-Hyung Woo; Csaba F László; Stephen Greco; Setsuko K Chambers
Journal:  Mol Cancer       Date:  2012-08-21       Impact factor: 27.401

View more
  18 in total

1.  Is Integrin Subunit Alpha 2 Expression a Prognostic Factor for Liver Carcinoma? A Validation Experiment Based on Bioinformatics Analysis.

Authors:  Liang Zhang; Yi Huang; JunJun Ling; Wenlei Zhuo; Zhen Yu; Yunbo Luo; Yi Zhu
Journal:  Pathol Oncol Res       Date:  2018-12-04       Impact factor: 3.201

2.  Identification of the EMT-Related Genes Signature for Predicting Occurrence and Progression in Thyroid Cancer.

Authors:  Qiang Li; Sheng Jiang; Tienan Feng; Tengteng Zhu; Biyun Qian
Journal:  Onco Targets Ther       Date:  2021-05-12       Impact factor: 4.147

3.  TMT-based proteomic analysis reveals integrins involved in the synergistic infection of reticuloendotheliosis virus and avian leukosis virus subgroup J.

Authors:  Xiyao Cui; Xinyue Zhang; Jingwen Xue; Yongxiu Yao; Defang Zhou; Ziqiang Cheng
Journal:  BMC Vet Res       Date:  2022-04-04       Impact factor: 2.741

4.  miR-330-5p suppresses glioblastoma cell proliferation and invasiveness through targeting ITGA5.

Authors:  Linsen Feng; Jianhua Ma; Haiming Ji; Yichun Liu; Weixing Hu
Journal:  Biosci Rep       Date:  2017-06-21       Impact factor: 3.840

5.  Prognostic Value of microRNA Signature in Patients with Gastric Cancers.

Authors:  Hai-Ting Liu; Ya-Wen Wang; Ai-Yan Xing; Duan-Bo Shi; Hui- Zhang; Xiang-Yu Guo; Jing- Xu; Peng Gao
Journal:  Sci Rep       Date:  2017-02-16       Impact factor: 4.379

6.  High G2 and S-phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis.

Authors:  Tianxiao Xu; Meng Ma; Zhihong Chi; Lu Si; Xinan Sheng; Chuanliang Cui; Jie Dai; Sifan Yu; Junya Yan; Huan Yu; Xiaowen Wu; Huan Tang; Jiayi Yu; Yan Kong; Jun Guo
Journal:  Cancer Sci       Date:  2018-05-11       Impact factor: 6.716

7.  Key signaling pathways, genes and transcription factors associated with hepatocellular carcinoma.

Authors:  Jingcheng Wang; Yang Tian; Hui Chen; Hui Li; Shusen Zheng
Journal:  Mol Med Rep       Date:  2018-04-12       Impact factor: 2.952

8.  Identification of CD20, ECM, and ITGA as Biomarkers for Osteosarcoma by Integrating Transcriptome Analysis.

Authors:  Da-Wei Wang; Sheng-Yuan Yu; Yang Cao; Lei Yang; Wei Liu; Xiao-Qiang Er; Gui-Jun Yao; Zheng-Gang Bi
Journal:  Med Sci Monit       Date:  2016-06-17

9.  MicroRNA-128 promotes apoptosis in lung cancer by directly targeting NIMA-related kinase 2.

Authors:  Dejian Zhao; Wenzheng Han; Xia Liu; Dawei Cui; Yu Chen
Journal:  Thorac Cancer       Date:  2017-05-17       Impact factor: 3.500

10.  MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway.

Authors:  Jingjin Jiang; Xiaoning Feng; Wenjing Zhou; Yue Wu; Yunmei Yang
Journal:  Oncotarget       Date:  2016-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.